Detection of IL-36? through noninvasive tape stripping reliably discriminates psoriasis from atopic eczema - 06/08/18
Doi : 10.1016/j.jaci.2018.04.031
Anna Berekméri, MD a, b, ∗, Anne Latzko, MSc a, c, ∗, Adewonuola Alase, PhD a, b, Tom Macleod, PhD c, Joseph S. Ainscough, PhD c, Philip Laws, MD b, Mark Goodfield, MD, FRCP b, Andrew Wright, MD, FRCP d, e, Philip Helliwell, PhD b, Sara Edward, FRCPath, Dip Dermpath f, Gordon D. Brown, PhD g, Delyth M. Reid, PhD d, Joerg Wenzel, MD h, Martin Stacey, PhD c, ‡, Miriam Wittmann, MD a, b, e, ‡ 
a Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom
c Faculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, United Kingdom
b National Institute of Health Research (NIHR), Leeds Biomedical Research Centre (BRC), Leeds Teaching Hospitals, Leeds, United Kingdom
d Bradford Teaching Hospital Foundation Trust, Bradford, United Kingdom
e Centre for Skin Sciences, University of Bradford, Bradford, United Kingdom
f St James's Institute of Oncology, St James's University Hospital, Leeds, Leeds, United Kingdom
g Medical Research Council Centre for Medical Mycology at the University of Aberdeen, Aberdeen Fungal Group, Institute of Medical Sciences, Aberdeen, United Kingdom
h Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany
Sous presse. Épreuves corrigées par l'auteur.
Disponible en ligne depuis le Monday 06 August 2018
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
| Supported mainly by a 2014 Pfizer Inflammation Competitive Research Programme (ICRP). In addition, assay development support was received by MRC grant MR/M01942X/1. G.D.B. and D.M.R. were funded by the Wellcome Trust (102705, 97377), the MRC Centre for Medical Mycology, and the University of Aberdeen (MR/N006364/1). Some of the samples included in the AD comparator group were acquired in the context of the National Institute for Health Research (NIHR)–funded ALPHA trial (EUDRACT 2014-004741-27) Explorative Biomarker substudy. The ALPHA trial was developed in collaboration with the Clinical Trials Research Unit at the University of Leeds with support from the UK Dermatology Clinical Trials Network (UK DCTN). The UK DCTN is grateful to the British Association of Dermatologists and the University of Nottingham for financial support of the Network. This research is also supported by the NIHR Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2018
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?